Company Reports Q1 Revenue of $67.38M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy SRTA?
Reports Q1 revenue $67.38M, consensus $63.67M. "We are pleased to report Q1 results that came in ahead of our expectations, reflecting both strong execution on our growth plan and improving industry dynamics," said Melissa Tomkiel, Co-CEO and General Counsel. "Operationally, we're making great progress optimizing how we deliver our end-to-end transplant service offering."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRTA
Wall Street analysts forecast SRTA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.340
Low
8.00
Averages
9.63
High
11.25
Current: 5.340
Low
8.00
Averages
9.63
High
11.25
About SRTA
Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, expanding its portfolio of services through acquisition and organic growth. The Company focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The Company also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strata Critical Medical Announces Expiration of Warrants
- Warrants Expiration: Strata Critical Medical announced that its Public Warrants (NASDAQ:SRTAW) and Private Placement Warrants expired at 5:00 p.m. ET on May 7, 2026, marking the end of this financing tool and potentially impacting future capital structure.
- Healthcare Service Network: Strata operates one of the largest air transport and surgical services networks in the U.S. healthcare industry, focusing on transplant hospitals and organ procurement organizations, which enhances the efficiency of organ recovery processes.
- Core Service Integration: The company's core services include air and ground logistics, surgical organ recovery, organ placement, and perfusion staffing and equipment solutions for cardiovascular surgery centers, showcasing its comprehensive capabilities in the medical services sector.
- Brand Strategy: Strata strengthens its market position in the transplant industry through its Trinity Medical Solutions and Keystone Perfusion brands, aiming to enhance customer satisfaction and competitive edge by integrating resources.
See More
Strata Critical Medical Reports Strong Q1 2026 Earnings with 87% Revenue Growth
- Significant Revenue Growth: Strata Critical Medical reported an impressive 87.4% year-over-year revenue increase in Q1 2026, reaching $67.4 million, with Logistics revenue rising 32.4% to $47.6 million, demonstrating the company's strong market performance and business expansion capabilities.
- Cash Flow Improvement: The company generated $3.9 million in operating cash flow and $2.1 million in free cash flow this quarter, marking a significant enhancement in cash generation capacity before aircraft acquisitions, with expectations for further improvements in earnings quality and cash conversion in upcoming quarters.
- Acquisition Strategy Advancement: The announcement of the $1 million acquisition of Ohio Valley Perfusion Associates is expected to contribute approximately $100,000 of adjusted EBITDA for the remainder of the year, showcasing the company's proactive approach to M&A and financial flexibility.
- Stable Outlook: Management reiterated its 2026 revenue guidance of $260 million to $275 million and adjusted EBITDA of $29 million to $33 million, maintaining confidence in future performance despite challenges from fuel price volatility and market demand fluctuations.
See More
Blade Air Mobility Q1 Earnings Exceed Expectations
- Earnings Beat: Blade Air Mobility reported a Q1 GAAP EPS of $0.03, exceeding expectations by $0.07, which indicates a significant improvement in profitability and boosts investor confidence.
- Strong Revenue Growth: Q1 revenue reached $67.4 million, a 24.1% year-over-year increase, surpassing market expectations by $3.73 million, reflecting the company's competitive edge and growth potential in the market.
- Logistics Performance: Logistics revenue and gross profit grew by 32.4% and 29.9% year-over-year, respectively, showcasing Strata's robust organic growth and solidifying its market position in medical logistics.
- Adjusted EBITDA Growth: Q1 adjusted EBITDA was $6.4 million with a net income of $2.4 million, indicating profitability in ongoing operations and strengthening the financial foundation for future expansion.
See More
Blade Air Mobility to Announce Q1 Earnings on May 6
- Earnings Announcement: Blade Air Mobility (SRTA) is set to announce its Q1 2023 earnings on May 6 before market open, with a consensus EPS estimate of -$0.04, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: Analysts project Blade Air Mobility's revenue to reach $63.67 million, reflecting a 17.3% year-over-year increase, suggesting potential sales growth in the market despite the anticipated losses.
- Strategic Expansion: Strata Critical Medical (SRTA) has raised its 2026 revenue guidance to between $260 million and $275 million, driven by 35% organic growth, showcasing the success of its acquisition strategy and strong market demand.
- Stock Price Reaction: Strata Critical Medical's stock surged by 21% following its Q4 earnings report, indicating investor optimism regarding its revenue growth and future prospects.
See More
Strata Critical Medical to Present at Needham Conference
- Conference Announcement: Strata Critical Medical will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 1:30 PM ET, showcasing its latest advancements in medical logistics, which is expected to attract investor and industry attention.
- Webcast Availability: The event will feature a webcast accessible through the company's investor relations section, ensuring transparency and enhancing engagement with investors, thereby improving the company's public image.
- Business Expansion: Strata Critical Medical is strategically expanding its service portfolio through acquisitions and organic growth, particularly highlighting its subsidiary Trinity Medical Solutions' leadership in organ transportation, demonstrating the company's strong competitive position in the healthcare services market.
- Forward-Looking Statements: The press release includes forward-looking statements that emphasize future growth opportunities and potential risks, indicating management's confidence in the company's future while also cautioning investors to consider external factors that may impact performance.
See More
Strata Critical Medical Reports Strong Q4 2025 Earnings
- Organic Growth Exceeds Expectations: Strata Critical Medical achieved a remarkable 35% organic growth in Q4 2025, with revenue reaching $66.8 million, surpassing expectations and demonstrating strong performance post-Keystone acquisition, thereby solidifying its market position in organ transportation.
- 2026 Guidance Raised: Management raised the 2026 revenue guidance to a range of $260 million to $275 million, with adjusted EBITDA guidance increased to $29 million to $33 million, reflecting ongoing customer growth and robust market demand, indicating enhanced future profitability.
- Acquisition and Asset Strategy: The company plans to add two dedicated aircraft in 2026 to support expansion into new markets while securing a $30 million asset-based credit facility to fund future acquisitions, showcasing its proactive approach in M&A activities.
- Regulatory Policy Benefits: Management highlighted that regulatory policies aimed at incentivizing more DCD donors are a clear positive for the company, leveraging its expertise in organ recovery and transportation to potentially increase market share and business growth opportunities.
See More
Strata Critical Medical Announces Expiration of Warrants
- Warrants Expiration: Strata Critical Medical announced that its Public Warrants (NASDAQ:SRTAW) and Private Placement Warrants expired at 5:00 p.m. ET on May 7, 2026, marking the end of this financing tool and potentially impacting future capital structure.
- Healthcare Service Network: Strata operates one of the largest air transport and surgical services networks in the U.S. healthcare industry, focusing on transplant hospitals and organ procurement organizations, which enhances the efficiency of organ recovery processes.
- Core Service Integration: The company's core services include air and ground logistics, surgical organ recovery, organ placement, and perfusion staffing and equipment solutions for cardiovascular surgery centers, showcasing its comprehensive capabilities in the medical services sector.
- Brand Strategy: Strata strengthens its market position in the transplant industry through its Trinity Medical Solutions and Keystone Perfusion brands, aiming to enhance customer satisfaction and competitive edge by integrating resources.
See More
Strata Critical Medical Reports Strong Q1 2026 Earnings with 87% Revenue Growth
- Significant Revenue Growth: Strata Critical Medical reported an impressive 87.4% year-over-year revenue increase in Q1 2026, reaching $67.4 million, with Logistics revenue rising 32.4% to $47.6 million, demonstrating the company's strong market performance and business expansion capabilities.
- Cash Flow Improvement: The company generated $3.9 million in operating cash flow and $2.1 million in free cash flow this quarter, marking a significant enhancement in cash generation capacity before aircraft acquisitions, with expectations for further improvements in earnings quality and cash conversion in upcoming quarters.
- Acquisition Strategy Advancement: The announcement of the $1 million acquisition of Ohio Valley Perfusion Associates is expected to contribute approximately $100,000 of adjusted EBITDA for the remainder of the year, showcasing the company's proactive approach to M&A and financial flexibility.
- Stable Outlook: Management reiterated its 2026 revenue guidance of $260 million to $275 million and adjusted EBITDA of $29 million to $33 million, maintaining confidence in future performance despite challenges from fuel price volatility and market demand fluctuations.
See More
Blade Air Mobility Q1 Earnings Exceed Expectations
- Earnings Beat: Blade Air Mobility reported a Q1 GAAP EPS of $0.03, exceeding expectations by $0.07, which indicates a significant improvement in profitability and boosts investor confidence.
- Strong Revenue Growth: Q1 revenue reached $67.4 million, a 24.1% year-over-year increase, surpassing market expectations by $3.73 million, reflecting the company's competitive edge and growth potential in the market.
- Logistics Performance: Logistics revenue and gross profit grew by 32.4% and 29.9% year-over-year, respectively, showcasing Strata's robust organic growth and solidifying its market position in medical logistics.
- Adjusted EBITDA Growth: Q1 adjusted EBITDA was $6.4 million with a net income of $2.4 million, indicating profitability in ongoing operations and strengthening the financial foundation for future expansion.
See More
Blade Air Mobility to Announce Q1 Earnings on May 6
- Earnings Announcement: Blade Air Mobility (SRTA) is set to announce its Q1 2023 earnings on May 6 before market open, with a consensus EPS estimate of -$0.04, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: Analysts project Blade Air Mobility's revenue to reach $63.67 million, reflecting a 17.3% year-over-year increase, suggesting potential sales growth in the market despite the anticipated losses.
- Strategic Expansion: Strata Critical Medical (SRTA) has raised its 2026 revenue guidance to between $260 million and $275 million, driven by 35% organic growth, showcasing the success of its acquisition strategy and strong market demand.
- Stock Price Reaction: Strata Critical Medical's stock surged by 21% following its Q4 earnings report, indicating investor optimism regarding its revenue growth and future prospects.
See More
Strata Critical Medical to Present at Needham Conference
- Conference Announcement: Strata Critical Medical will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 1:30 PM ET, showcasing its latest advancements in medical logistics, which is expected to attract investor and industry attention.
- Webcast Availability: The event will feature a webcast accessible through the company's investor relations section, ensuring transparency and enhancing engagement with investors, thereby improving the company's public image.
- Business Expansion: Strata Critical Medical is strategically expanding its service portfolio through acquisitions and organic growth, particularly highlighting its subsidiary Trinity Medical Solutions' leadership in organ transportation, demonstrating the company's strong competitive position in the healthcare services market.
- Forward-Looking Statements: The press release includes forward-looking statements that emphasize future growth opportunities and potential risks, indicating management's confidence in the company's future while also cautioning investors to consider external factors that may impact performance.
See More
Strata Critical Medical Reports Strong Q4 2025 Earnings
- Organic Growth Exceeds Expectations: Strata Critical Medical achieved a remarkable 35% organic growth in Q4 2025, with revenue reaching $66.8 million, surpassing expectations and demonstrating strong performance post-Keystone acquisition, thereby solidifying its market position in organ transportation.
- 2026 Guidance Raised: Management raised the 2026 revenue guidance to a range of $260 million to $275 million, with adjusted EBITDA guidance increased to $29 million to $33 million, reflecting ongoing customer growth and robust market demand, indicating enhanced future profitability.
- Acquisition and Asset Strategy: The company plans to add two dedicated aircraft in 2026 to support expansion into new markets while securing a $30 million asset-based credit facility to fund future acquisitions, showcasing its proactive approach in M&A activities.
- Regulatory Policy Benefits: Management highlighted that regulatory policies aimed at incentivizing more DCD donors are a clear positive for the company, leveraging its expertise in organ recovery and transportation to potentially increase market share and business growth opportunities.
See More
